Eiger Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2023 to Discuss Your Rights – EIGR

Nov 23rd, 2022 15:24 EST

New York, New York--(Newsfile Corp. - November 23, 2022) - Levi & Korsinsky, LLP notifies investors in Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR) of a class action securities lawsuit.

The lawsuit on behalf of Eiger investors has been commenced in the the United States District Court for the Northern District of California. Affected investors purchased or otherwise acquired certain Eiger BioPharmaceuticals, Inc. securities between March 10, 2021 and October 4, 2022. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/eiger-biopharmaceuticals-class-action-lawsuit-submission-form?prid=34023&wire=5

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you.

Eiger BioPharmaceuticals, Inc. NEWS - EIGR NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) defendants overstated Eiger's clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization ("EUA") for the Company's product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda's regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Eiger during the relevant timeframe, you have until January 9, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/eiger-biopharmaceuticals-class-action-lawsuit-submission-form?prid=34023&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.Ed Korsinsky, Esq.55 Broadway, 10th FloorNew York, NY 10006[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/145497

SHARE

You must be logged in to post a comment.

Related Recent Publications

You must be logged in to post a comment.

Email newsletter

Receive the latest stock news and signals